2025-09-25 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you provided, formatted as requested.

## Johnson & Johnson (JNJ) Stock Analysis

Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 37.69%
*   **VOO Cumulative Return:** 69.58%
*   **Return Disparity:** -31.89%
*   **Disparity Range:** Max: 20.0, Min: -83.0, Current: -77.3
*   **Relative Disparity:** 5.5

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the period reflected in the cumulative returns.  The return disparity of -31.89% indicates a substantial lag. The Relative Disparity of 5.5 suggests that JNJ's underperformance is near its historical worst relative to the S&P 500 based on the provided range.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha   | Beta  | Cap(B) |
|------------|----------|----------|---------|-------|--------|
| 2015-2017  | 22.0%    | 77.4%    | -3.0%   | 0.1   | 336.5  |
| 2016-2018  | 10.0%    | 75.5%    | -8.0%   | 0.0   | 310.8  |
| 2017-2019  | 16.0%    | 75.5%    | -10.0%  | 0.5   | 351.3  |
| 2018-2020  | 7.0%     | 75.5%    | -4.0%   | 0.6   | 379.1  |
| 2019-2021  | 28.0%    | 83.8%    | -1.0%   | 0.7   | 412.0  |
| 2020-2022  | 9.0%     | 99.0%    | 14.0%   | 0.5   | 425.5  |
| 2021-2023  | -5.0%    | 99.0%    | -16.0%  | 0.3   | 377.5  |
| 2022-2024  | -27.0%   | 99.0%    | -51.0%  | 0.2   | 348.3  |
| 2023-2025  | 13.0%    | 99.0%    | -27.0%  | 0.1   | 424.9  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** Varies significantly across the periods.
*   **MDD (Maximum Drawdown):** Consistently high, indicating substantial risk of loss during these periods.  MDD has been very high in recent periods.
*   **Alpha:**  Mostly negative, implying underperformance relative to its benchmark (S&P 500). The most recent periods show large negative alpha.
*   **Beta:** Generally low (close to 0), suggesting low market sensitivity.
*   **Cap(B):** Shows the company's market capitalization in billions.

### 2. Recent Stock Price Action

*   **Current Price:** 176.43
*    **Last-market:** {'price': 176.445, 'previousClose': 176.58, 'change': -0.08}
*   **5-day Moving Average:** 175.638
*   **20-day Moving Average:** 176.8765
*   **60-day Moving Average:** 170.2532

**Analysis:**

*   The current price is slightly below the 20-day moving average but above the 5-day and 60-day moving averages. This suggests potential short-term price weakness but medium-term strength.
*   The price decreased slightly on the last market day, but the change is minimal.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.434 (Medium Risk)
*   **RSI:** 45.75 (Neutral)
*   **PPO:** -0.3765 (Potentially Bearish)
*   **Hybrid Signal:** Cash_86%_Sell 16.3% of holdings (27 shares - Very Risky - MRI:0.43) (Cash Ratio: 86% on 2025-09-23)
*   **Recent (20-day) Relative Disparity Change:** -2.8 (Short-term decline)
*   **Expected Return:** -579.9% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI indicates a medium level of risk.
*   The RSI is neutral, not indicating overbought or oversold conditions.
*   The negative PPO might indicate a potential downtrend.
*   The Hybrid Signal suggests reducing holdings significantly, with a very high cash ratio, reflecting a bearish outlook.
*   The negative change in relative disparity indicates recent underperformance.
*   The very negative expected return indicates a highly pessimistic long-term outlook relative to the S&P 500.
*   The minimal price change on the last market day suggests no immediate, dramatic volatility.

### 4. Recent News & Significant Events

*   **Kenvue (Tylenol) Crisis:**  Negative news related to Johnson & Johnson's spin-off, Kenvue, could indirectly impact JNJ's reputation.
*   **Wall Street Views:**  Some analysts have a bullish outlook on JNJ.
*   **Stryker Growth:**  This news about a competitor could highlight areas where JNJ needs to innovate or improve.
*   **Valuation Justification:**  Indicates questions about whether JNJ's current price is supported by its fundamentals.
*   **Analyst Report (Morningstar):**  A potentially valuable source of in-depth analysis.
*   **Abiomed Recall:**  Quality control issues are always a concern.  Multiple recalls raise red flags.

**Analysis:** The news is mixed, with some positive analyst sentiment but also concerning news regarding a spin-off's issues and recalls related to a subsidiary's product. This mixed news environment creates uncertainty.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (2.17 on scale of 1-5)
*   **Target Price:** Average: 179.64, High: 206.00, Low: 155.00
*   **Recent Rating Changes:** No changes in the provided data

**Analysis:**  Analysts, on average, have a "Buy" rating. The average target price suggests a potential upside from the current price. However, the range of target prices is wide, reflecting uncertainty. The lack of recent rating changes suggests no major shifts in sentiment.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-07-24 | 2.3  | 23.74 B$    |
| 2025-04-23 | 4.57 | 21.89 B$    |
| 2024-10-23 | 1.12 | 22.47 B$    |
| 2024-07-25 | 1.95 | 22.45 B$    |
| 2025-07-24 | 1.95 | 22.45 B$    |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated. The most recent quarter (2025-07-24) shows an EPS of 2.3 and revenue of $23.74B. It's crucial to analyze these figures relative to previous years and analyst expectations.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $23.74B    | 67.87%       |
| 2025-03-31   | $21.89B    | 66.40%       |
| 2024-12-31   | $22.52B    | 68.35%       |
| 2024-09-30   | $22.47B    | 69.01%       |
| 2024-06-30   | $22.45B    | 69.40%       |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-06-30   | $78.47B    | 7.06%    |
| 2025-03-31   | $78.11B    | 14.08%   |
| 2024-12-31   | $71.49B    | 4.80%    |
| 2024-09-30   | $70.16B    | 3.84%    |
| 2024-06-30   | $71.54B    | 6.55%    |

**Analysis:**

*   **Revenue:**  Shows some variability across quarters.
*   **Profit Margin:**  Consistently high, indicating strong profitability.
*   **Equity:**  Fluctuates, with recent increases.
*   **ROE (Return on Equity):**  Also fluctuates, indicating variability in the company's ability to generate profit from shareholder equity. The ROE was particularly strong in 2025-03-31.

### 7. 종합적 분석

Johnson & Johnson (JNJ) presents a mixed picture based on the provided data. While analysts maintain a "Buy" rating and the company exhibits strong profit margins, several concerning factors emerge:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500, and its expected return is highly negative.
*   **Technical Indicators:** The hybrid signal suggests a bearish outlook, and the negative PPO reinforces this concern.
*   **News and Events:** The Kenvue crisis and Abiomed recalls raise questions about brand reputation and product quality.
*   **Volatility:** High MDD values indicate significant price volatility and potential for large losses over the analyzed periods.
*   **Mixed Analyst Views:** Despite the "Buy" consensus, the wide range in target prices reflects significant uncertainty about the stock's future performance.

**Conclusion:**

Based on this analysis, investing in JNJ appears risky at the moment. The underperformance relative to the S&P 500, negative expected return, and concerning news headlines suggest caution. While the analyst consensus is positive, the technical indicators and financial data point to potential challenges. It's crucial to conduct further in-depth research, consider your risk tolerance, and monitor the company's progress in addressing the identified issues before making an investment decision.
